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Introduction
A drug interaction occurs when the effect of a drug is altered
by other drugs; it may affect the drug’s pharmacokinetics or
pharmacodynamics.1 In pharmacokinetic interactions, a drug
alters the absorption, distribution, metabolism, or excretion of
another drug; in pharmacodynamic interactions, the action of a
drug is altered by other drugs.2 The occurrence and the
severity of a drug interaction is affected by many factors such
as the number of prescribed drugs, treatment duration,
patient’s age, disease stage, and the number of physicians
prescribing the drugs.1,3 Critically ill patients are particularly
prone to drug interactions, as they have several related risk
factors such as higher age, multidrug therapy, and long
duration of hospital stay.1,2,4-6
Almeida et al1 conducted a study on the assessment of drug-
drug interactions in the adult intensive care unit (ICU) of a
large private tertiary care hospital over a period of 30 days.
They reported that potential drug interactions are common in
ICU patients and may potentially produce a significant
economic and clinical impact. In another study carried out by
Rais et al in 2011, drug interactions in three different time
periods were studied.7 They reported a high prevalence of drug
interactions in ICU, and found that factors such as the number
of drugs taken, the duration of stay in ICU, and the types of
drugs used were the most important factors. Moura et al
studied the correlation between drug interactions and the
duration of stay in the ICU.8 They reported that patients
staying longer in ICU suffer more from drug interactions. In
our previous study, we observed a high risk of drug interaction
in patients after the first 24 hours in ICU. In addition, we
found that reasons such as number of administered drugs, the
number of physicians visiting a patient, and the patients’ ages,
were the most important factors increasing the risk of drug
interactions in ICU patients.9
Although drug interactions have already been studied in
ICU, most of these studies were limited in two ways – either
they considered theoretical interactions without taking account
of the duration of action of the drugs and/or they ignored
beneficial drug interactions. As an example of the first
limitation, a theoretical interaction between two drugs (one
administered in the morning and the other in the evening) was
considered a drug interaction, which might not be the case
considering the duration of the effect of the drugs. The second
confounder, which has been ignored in previous studies, was
beneficial drug interactions, ie interactions which the medical
team had been aware of and had intentionally used. For
example Reis et al have reported severe drug interactions
between fentanyl and midazolam, without considering this was
probably intentional.7
The aim of the current study was to determine the
prevalence of drug interactions in different work shifts and also
to determine the number of beneficial versus harmful
interactions in ICU patients.
Methods
This cross-sectional study was approved by the ethical
committee of Kerman Medical University. Each patient (if the
patient was able to respond) or their relative, was asked to fill
in a written consent form. All research in Iran requires
approval by a local ethical committee. These committees
usually comprise about 20 people who are specialist nurses or
doctors. In the Iranian healthcare system, hospitals and their
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ICUs are categorised in three levels. This study was performed
in a level one unit. In such a unit the head must be an
intensivist. These ICUs usually have more than 20 beds. The
Iranian Society of Intensive and Critical Care Medicine is
responsible for designing programmes and guidelines for ICU,
but has no guidance regarding drug-drug interactions.
Sampling was done in four distinct time periods in three
different work shifts – morning, evening, and night. Our
previous studies in the same hospital had shown that the
average duration of stay in ICU was about 18 days.9,10
Therefore, four distinct samplings were done at intervals of 20
days. To collect the required data, the ICU flow sheets
completed by the ICU nurses were used because they were
considered the most reliable. The data on the number of drugs
taken, the name of the drugs, the routes of administration, and
demographic variables, including the patients’ age and gender,
were obtained. The extent of occurrence and frequency of
potential drug interactions were investigated based on the
reference textbook ‘Drug Interaction Facts’ published in 2010.11
This textbook is considered the gold standard for identifying
drug interactions in Iran. 
Potential drug interactions identified were classified by: 
• severity
– minor: ‘the effects are usually mild; consequences may be
bothersome or unnoticeable but should not significantly
affect the therapeutic outcome. Additional treatment is
usually not required’
– moderate: ‘the effect may cause deterioration in a patient’s
clinical status. Additional treatment, hospitalisation or an
extended hospital stay may be necessary’ 
– major: ‘the effects are potentially life-threatening or
capable of causing permanent damage’.
• onset of action
– rapid: ‘the effect will be evident within 24 hours of
administration of the interacting drug’ 
– delayed: ‘the effect will not be evident until the
interacting drug is administered for a period of days or
weeks’.
• documentation
– established: ‘proven to occur in well controlled studies’
– probable: ‘very likely but not proven clinically’ 
– suspected: ‘may occur; some good data; need more study’ 
– possible: ‘could occur but data are limited’
– unlikely: ‘doubtful; no good evidence of an altered
clinical effect’. 
According to this textbook drug interactions, which the
medical team had been aware of and had been intentionally
induced to gain advantage, were considered beneficial
interactions (eg, interactions between antibiotics). Interactions
that the medical team had not been aware of were considered
harmful. Nutritional supplements, ointments, drops, serums,
electrolytes, and vitamins were excluded from the data
collection. Drugs which are not registered in the textbook were
considered to be without potential drug interaction All data
were analysed using SPSS 18·00 statistical software and a
variable was found to be statistically significant if p <0·05.
Descriptive statistics (expressed as mean and standard
deviation (SD)), Pearson correlation test and independent t-test
were used.
Results
The sample consisted of 101 patients, 75.2% of whom were
men. The mean age was 37.2 ± 21.5 years. The mean number
of administered drugs for each patient was 23.6 ± 9.1. Of all
the drugs administered, 44.5% were during the morning shifts,
23.3% in evening shifts, and 32.2% in night shifts. Overall
58.5% of the drugs were injected and the rest taken orally. Six
hundred and nine drug interactions were documented in
patients’ flow sheets (6.1 ± 5.6 per patient). Of all the drug
interactions, 66.9% were potentially harmful, and 33.1%
beneficial. Of 202 beneficial drug interactions, 100 cases were
related to interaction between phenytoin and midazolam. In
terms of distribution among various work-shifts, 53% of
interactions were in the morning shifts, 16.1% in the evening
shifts, and 30.9% in the night shifts. With regard to the types
of interactions, most of the interactions were of delayed,
moderate, and possible types. Table 1 shows the types of
interactions in terms of starting time, severity, and the degree
of proof in the three various shifts. In terms of the number of
drug interactions, the highest frequency of interaction occurred
between phenytoin and omeprazole, (Table 1). Of all the
interactions, 15 were major (Table 3) and 74 cases of
Classification Morning Evening Night
Severity Major 8 2.4% Major 4 4.0% Major 3 1.6%
Moderate 230 71.1% Moderate 73 73.7% Moderate 152 81.3%
Minor 85 26.5% Minor 22 22.3% Minor 32 17.1%
Onset of action Rapid 36 11.1% Rapid 18 18.1% Rapid 20 10.6%
Delayed 287 88.9% Delayed 81 81.9% Delayed 168 89.4%
Documentation Established 23 7.1% Established 10 10.1% Established 15 8.9%
Probable 21 6.5% Probable 6 6.1% Probable 8 4.8%
Possible 143 44.3% Possible 50 50.3% Possible 84 50.0%
Suspected 127 39.4% Suspected 25 25.1% Suspected 53 31.5%
Unlikely 9 2.7% Unlikely 8 8.1% Unlikely 8 4.8%
Table 1 Drug interactions classified by severity, onset of action and documentation.
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interaction were rapid (Table 4). Among the drugs used in the
ICU, the most frequently used ones were morphine (222
times), phenytoin (170 times), and midazolam (155 times).
Drug reactions appeared to be commoner among men than
women (7.1 vs 6.2) but this was not confirmed statistically.
Pearson correlation test showed a significant correlation
between number of potential drug interactions and number of
prescribed drugs (r=0.561, p<0.05).
Discussion
There were 690 interactions documented confirming that ICU
patients are at high risk of this complication. Although the
findings showed that approximately one third of the
interactions were beneficial, it remains important for the
clinical team to remain aware of all reactions. 
Previous studies have reported that the incidence of drug
interactions is high in ICU patients,1,2,4-6,12 however, there
remains controversy. For example, in our previous study, we
assessed drug interactions only in the first 24 hours after
admission.9 We reported that on average, each patient received
5.6 drugs, which is lower than what we found in the current
study (23.6 drugs per patient). Unsurprisnigly therefore, the
6.1 drug interactions per patient, observed in this study, is
more than reported in our previous study (mean of 1.9
interactions per patient).9 Apparently, the longer the patients
stay in ICU, the higher the number of drugs is prescribed and
the greater the possibility for drug interactions. 
Results of the present study showed that the most common
type of potential drug interactions among critically ill patients
were delayed, moderate and possible. Similarly, Hammes et al
found that 59.7% of potential drug interactions in ICU are
delayed.4 They also reported that moderate and possible
interactions are higher than other types of interactions among
critically ill patients.4 This issue could be explained by two
facts: phenytoin was responsible for a high percentage of
interactions in our study, and phenytoin’s interactions are
mostly delayed, moderate, and possible; therefore these types
of interactions would be more frequent than others. 
The interaction between phenytoin and omeprazole is the
most frequent in our study. Phenytoin and omeprazole are the
most common anticonvulsant and antacid drugs used in the
ICU respectively.13.14 Omeprazole inhibits CYP2C19 and
decreases the clearance of phenytoin.15 In Iranian ICUs both
phenytoin and omeprazole are administered enterally.
Omeprazole is administered once daily (9 am) and phenytoin
three doses daily (9 am, 5 pm and 1 am). Omeprazole has a
short plasma half-life (0.5-2 hours),15 but considering the use
of omeprazole and phenytoin simultaneously (9 am), the
chance of an actual interaction between the two drugs in
patients in the present study is high. 
In line with the results obtained by other studies1,2,5 the
present study found that the risk of drug interactions increased
with increasing number of prescribed drugs for patients. It
seems intuitive that with increasing numbers of prescribed
drugs there would be an increased rate of drug reactions, but in
addition critically ill patients are often seen by many different
clinicians who may prescribe without proper consideration of
the risk of interactions. 
Conclusion
Critically ill patients are at a high risk of drug interactions.
Although one-third of drug interactions were beneficial,
medical teams should be aware that even beneficial interactions
could have unfavorable side effects in the critically ill. Factors
such as multidrug therapy, administering phenytoin,
Drug Interaction (n) Type of interaction Drug Interaction Type of interaction
Phenytoin + omeprazole (63) Delayed, moderate, possible Paracetamol + phenytoin (24) Delayed, moderate, suspected
Omeprazole + midazolam (52) Delayed, minor, suspected Furosemide + phenytoin (19) Delayed, minor, suspected
Phenytoin + dexamethasone (39) Delayed, moderate, established Methadone + phenytoin (16) Delayed, moderate, suspected
Metronidazole + phenytoin (31) Delayed, moderate, possible Ranitidine + midazolam (12) Delayed, moderate, possible
Ranitidine + phenytoin (29) Delayed, moderate, possible Haloperidol + phenytoin (8) Rapid, minor, unlikely
Table 2 Ten most common harmful drug interactions.
Drug Interaction (n) Type of interaction
Furosemide + amikacin (6)  Rapid, major, probable
Atracurium + amikacin (5) Rapid, major, probable
Furosemide + tobramycin (3) Rapid, major, probable
Furosemide + digoxin (1) Delayed, major, probable
Table 3 List of harmful major drug interactions.
Drug Interaction (n) Type of interaction Drug interaction (n) Type of interaction
Ranitidine + midazolam (16) Rapid, minor, unlikely Theophylline + midazolam (5) Rapid, minor, suspected
Atracurium + vancomycin (12) Rapid, moderate, probable Omeprazole + theophylline (6) Rapid, minor, probable
Atracurium + phenytoin (8) Rapid, moderate, probable Atracurium + amikacin (5) Rapid, major, probable
Erythromycin + midazolam (6) Rapid, moderate, suspected Furosemide + ciprofloxacin (5) Rapid, minor, possible
Furosemide + amikacin (8) Rapid, major, probable Furosemide + tobramycin (3) Rapid, major, probable
Table 4 List of harmful rapid drug interactions.
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omeprazole, dexamethasone, furosemide, atracurium,
midazolam, amikacin, and paracetamol simultaneously,
absence of clinical pharmacologists, high number of
prescribing physicians and poor knowledge of medical and
nursing teams could all be important causes. Use of suitable
software to detect drug interactions may be helpful in
decreasing rate of drug interactions in ICU, although this
needs more study. Finally, it is important to highlight that drug
interactions and their side-effects could be lethal and costly;
therefore it is necessary to limit this risk through correct
planning by the medical and nursing team.
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